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To elucidate the biological signiﬁcance of activating mutations of BRAF in human malignant tumors, we performed
a mutation analysis using 43 cell lines established from tumors that had developed in several kinds of human
organs. Because the same V599E point mutation was observed in three of six melanoma cell lines and no such
mutations were observed in other types of cancers, we focused further on melanoma, performed mutation analyses
of NRAS, KRAS, CTNNB1, and p16/p14ARF in these cell lines, and found one NRAS mutation and three p16/p14ARF
mutations. We further searched for mutations of BRAF and NRAS in 35 primary sporadic melanomas from 35
Japanese patients and detected the V599E BRAF point mutation in only nine (26%) of them. Signiﬁcant differences
in mutation frequency were observed among four histological subtypes; four (50%) of eight superﬁcially spreading
melanoma and ﬁve (33%) of 15 acral lentiginous melanoma had the mutation, whereas none of 12 other types (six
nodular melanoma, ﬁve lentigo melanoma, and one mucosal melanoma) had it. The BRAF mutation was observed
frequently even in small lesions, indicating that activation of this gene may be one of the early events in the
pathogenesis of some melanomas.
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The RAF family (RAF1, ARAF1, and BRAF) genes encode
proteins that have cytoplasmic serine/threonine kinase
activity and are involved in the regulation of the signaling
cascade from the cell surface to the nucleus in response to
extracellular signals. BRAF works in the MAPK pathway that
transmits the signal from active RAS to MEK1/2 (Kolch,
2000; Avruch et al, 2001; Peyssonnaux et al, 2001).
Recently, Davies et al (2002) reported frequent somatic
missense activating mutations of BRAF in melanoma; 20
(59%) of 34 in melanoma cell lines and six (67%) of nine
primary melanomas harbored the mutation. Most of the
mutations were a T1796A transversion in exon 15 that
results in a V599E alteration, which would initiate BRAF
kinase activity and acquire transforming activity in NIH 3T3
cells. On the other hand, this BRAF germline point mutation
was absent in familial melanoma pedigrees or multiple
primary melanoma patients without familial histories (Lang
et al, 2003; Laud et al, 2003).
To date, mutation of the BRAF gene has been reported in
melanomas and colorectal cancers (Rajagopalan et al,
2002). RAS and RAF are closely related in the MAPK
pathway (Kolch, 2000; Peyssonnaux et al, 2001), and
mutations of these molecules are also reported in these
tumor types (Bos et al, 1987; Davies et al, 2002). Activating
mutations of these genes seem to be mutually exclusive,
suggesting that the protein products of these genes are
working in the same pathway. But not much information
about BRAF activation has been reported in tumors other
than melanomas and colorectal cancers. For these reasons,
we first studied several other cancer cell lines as well as
melanoma cell lines that are more or less associated with
activating mutations of the RAS pathway; only melanomas
showed frequent mutations of BRAF. We further focused on
melanoma to examine the question of whether there is
some association between histological subtype and acti-
vating mutation.
Results
Mutation analysis of BRAF in 43 cancer cell lines We
first analyzed mutations of the BRAF gene at the hot spots
in exons 11 and 15 along with the surrounding introns by
direct sequencing in 43 cancer cell lines; 23 lung cancer,
five gastric cancer, three malignant lymphoma, six endo-
metrial cancer, and six melanoma. Typical examples of the
sequencing analyses are shown in Fig 1A. A melanoma cell
line CRL1579 had a T to A transversion at the 1796th
nucleotide in exon 15 (T1796A) that would cause amino acid
change to glutamic acid from valine (V599E). The same
V599E mutation was observed in G361 and was accom-
panied by loss of the wild-type allele (see Fig 1A). We
confirmed the V599E mutation in SK-MEL-28 that was1These authors contributed equally to this work.
Abbreviations: SSM, superficially spreading melanoma; ALM, acral
lentiginous melanoma
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reported previously (Davies et al, 2002). Mutations were
observed only in these three melanoma cell lines; no
mutations were observed in the other types of cancer cell
lines.
In two of three melanoma cell lines with BRAF mutation
concurrently had p16/p14ARF mutation Therefore, we
focused further on melanoma and surveyed mutations of
p16/p14ARF, CTNNB1, NRAS, and KRAS in these six
Figure 1
Results of mutation search in the BRAF and p16/
p14ARF genes by nucleotide sequencing analysis.
(A) Nucleotide sequences of the sense strand of the
BRAF (NM 004333) exon 15 in DNAs of two melanoma cell
lines (CRL1579 and G361) and primary tumors (17T, 18T)
are shown. Each arrowhead at the underlined codon
indicates altered base. (B) Nucleotide sequences of the
sense strand around the stop codon of p16/p14ARF
(BC015960) in exon 3 are shown. A G to C transversion
at the second nucleotide of the stop codon indicated by
an underline and a red arrowhead causes an addition of
13 amino acids in the C terminus of the predicted protein
product in CRL1579 (Left). Normal nucleotide sequence
from SK-MEL-28 is shown in the right side. (C) Sequenc-
ing analysis showed a deletion of a 26-bp fragment in
exon 2 of the p16/p14ARF (BC015960) gene, accompanied
by loss of the wild-type allele, in DEOC-1. Upper
sequence represents the normal DNA sequence. Nucleo-
tide sequences of the sense strand are shown.
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melanoma cell lines. These genes were selected because
(1) associations with familial and sporadic melanomas were
previously reported and (2) these genes encoded the
molecules associated with BRAF in the MAPK pathway
(Ball et al, 1994; Kamb et al, 1994; Rubinfeld et al, 1997;
Demunter et al, 2001; Houghton et al, 2002; Reifenberger
et al, 2002). Among the results, three cell lines (G361,
CRL1579, and DEOC-1) had two-hit mutations in p16/
p14ARF, as shown in Figs 2 and 1B, C. One cell line,
CRL1579, also showed a G to C transversion at the stop
codon (X106S), resulting in the addition of a 13 amino acid
stretch (SKNQRGSEKPRET) in the C terminus of the
predicted p16 protein (see Fig 1B). This cell line also had
a homozygous deletion in exons 1 and 2.
We detected a NRAS mutation at codon 61 (Q61K) in one
cell line, HMV-II, as reported by Davies et al (2002), but no
more mutations were observed. These results are also
summarized in Table I. G361 and CRL1579 had mutations in
both BRAF and p16/p14ARF. Among the four cell lines with
mutations in the genes analyzed, two (50%) had mutations
in both of the two genes. But mutations in the RAS–RAF
pathway were mutually exclusive; no tumor had mutations
in both of the RAS and RAF genes.
Mutation analyses of BRAF and NRAS in primary
melanomas We next performed mutation analyses in 35
primary tumor specimens of melanoma. As the amounts of
sample DNAs were limited, we only could perform mutation
analyses of exons 11 and 15 of the BRAF gene and exons 2
and 3 of the NRAS gene. The V599E mutation in the BRAF
gene was observed in nine (26%) of 35 primary tumors by
direct sequencing analysis. Typical examples are also
shown in Fig 1A. Tumor 17T had a heterozygous mutation,
whereas 18T had a mutation accompanied by loss of the
wild-type allele. These results were consistent with those of
ASO hybridization, and the observed alterations were
confirmed as being somatic events (see Fig 3A and B).
Significant associations between mutation and histological
subtypes were observed as summarized in Table II;
mutation frequencies in superficially spreading melanoma
(SSM) and acral lentiginous melanoma (ALM) were sig-
nificantly high when compared with other types of melano-
ma (p¼ 0.012). In the nine patients with mutations in the
BRAF gene, three patients were at stage I (IA in one case
and IB in two cases), five were at stage II (IIA in two cases
and IIB in three cases), and one was at stage III B according
to AJCC 2002 pathological staging (Kim et al, 2002). No
mutations in the NRAS gene were detected.
Discussion
Our study provides some information of potential impor-
tance. First, the mutation frequency in the BRAF gene in the
primary melanoma was lower than those of several previous
reports of melanomas (Pollck et al, 2001; Davies et al, 2002;
Lang et al, 2003). Second, we found a significant difference
in mutation frequency by melanoma subtype. Notably, we
observed frequent mutations in SSM and ALM but no
mutations in the other histological subtypes. Third, muta-
tions were frequent in samples at relatively early stages of
melanoma, before metastasis to lymph nodes. Fourth,
mutations of the p16/p14ARF and BRAF were not mutually
exclusive, whereas those of BRAF and RAS were exclusive.
Since Davies et al (2002) found the BRAF gene mutations
in six (67%) of nine melanoma cell lines, little further
information has become available about the frequency of
BRAF point mutations in primary melanoma. Pollock et al
(2002) reported mutations in four (80%) of five primary
melanomas. We found BRAF point mutation in nine (26%) of
35 primary melanomas, a lower frequency than those of
previous reports. The reasons for this may be accounted for
by the differences in histological subtypes between Japa-
nese patients and others that have been reported. Recently,
Laud et al (2003) and Lang et al (2003) reported the absence
Figure 2
Detection of homozygous deletion of the p16/p14ARF gene by
multiplex PCR in melanoma cell lines. Results of multiplex PCR. Lane
1, HMV-I; Lane 2, HMV-II; Lane 3, SK-MEL-28; Lane 4, G361; Lane 5,
CRL1579; Lane 6, DEOC-I; Lane 7, negative control. Primers of p16/
p14ARF exon 3 and BRAF exon 15 are used.
Table I. Results of sequence analysis in 6 melanoma cell lines
Cell line
BRAF KRAS NRAS CTNNB1
p16/p14ARFExon 11 Exon 15 Codon 12 Codon 12 Codon 61 Exon 3
HMV-I WT WT WT WT WT WT WT
HMV-II WT WT WT WT Q61Ka WT WT
SK-MEL-28 WT V599Ea WT WT WT WT WT
G361 WT V599E WT WT WT WT HDb
CRL1579 WT V599E WT WT WT WT HDc
DEOC-1 WT WT WT WT WT WT 26-bp deldþ loss
aReported by Davies et al (2002).
bHomozygous deletion in exons 1 through 3.
cHomozygous deletion in exons 1 and 2 accompanied by X106S in exon 3.
dA 26-bp deletion in exon 2.
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of this alteration as a germline mutation in familial
melanoma. Likewise, in our series of patients, no germline
mutations were observed. It is possible that germline-
activating mutation of the BRAF gene causes serious
problem(s) in fetal development. Laud et al (2003) also
detected T1796A mutations in six (25%) of 24 sporadic
melanoma samples; this frequency of the mutation in the
BRAF gene was similar to that in our observations.
As seen in the data in Table II, the nine mutated cases in
this study included four (50%) of eight cases of SSM and
five (33%) of 15 cases of ALM; V599E is significantly
frequent in these subtypes. Thus, mutations of BRAF were
slightly more frequent in SSM (50%) than ALM (33%). In
examining the prevalence of melanoma in Japan, Kukita et al
(1989) reported that 41.9% of 833 cases of melanoma in
Japanese patients were classified as ALM, and 11.8% were
classified as SSM. In contrast, only 10.0% of the patients in
US were ALM and 69.6% were classified as SSM (Kukita
et al, 1989). This obvious difference in the highest frequency
of melanoma subtype between Japan and US may be
correlated with the difference in BRAF mutation frequencies
between the two countries.
There is little information about the timing of the
occurrence of BRAF mutation. Rajagopalan et al (2002)
reported that activating mutations in BRAF and KRAS in
colorectal cancers occurred at a rather early stage and were
mutually exclusive. This information suggests that the RAF
and RAS proteins play important roles in the same pathway
(MAPK pathway) and that activation of this pathway is an
early event in the pathogenesis of melanomas. Our results
agree with their findings; none of our samples harbored
mutations in both of these genes. Three of the nine samples
with a BRAF mutation in this study belonged to stage I. We
could not prepare any in situ melanoma samples, but it is
probable that BRAF point mutations begin at a relatively
early stage. Recently, Pollock et al (2003) reported that they
detected a BRAF point mutation in 82% of nevi. Nevi are
distinct from melanoma, and, in general, they are not
believed to be sequential diseases, but these data support
the argument that a BRAF mutation alone is insufficient to
transform a melanocyte into melanoma.
We also observed two-hit mutations of p16/p14ARF in
three melanoma cell lines; among these, two cell lines also
had mutations in BRAF. Inactivation of p16/p14ARF is also
one of the important events in the pathogenesis of
melanoma and acts in a pathway distinct from that of
Figure 3
Results of mutation analysis by ASO hybridiza-
tion. (A) ASO hybridization of the synthetic
oligonucleotide probe for BRAF. RAF-MS corres-
ponding to the V599E mutation was used. The lane
number is consistent with the patient’s number.
SK-MEL-28 and HMV-II are used as positive and
negative controls. (B) ASO hybridization to ampli-
fied BRAF exon 15 from the normal and tumor
tissues derived from the nine patients with muta-
tions of the BRAF gene in primary melanoma.
Primers RAF-MS, detecting V599E mutation, and
RAF-NS, corresponding to the normal sequence,
were used. Nucleotide sequences are shown in
Table IV.
Table II. Frequencies of BRAF mutation in primary melanomas
Type of melanoma Incidence of mutation
ALM 5/15 (33%)
SSM 4/8 (50%)
NM 0/6 (0%)
LMM 0/5 (0%)
Mucosal 0/1 (0%)
Total 9a/35 (26%)
aNine patients were classified based on the AJCC pathological staging
system: 1 in stage IA, 2 in stage IB, 2 in stage IIA, 3 in stage IIB, and 1 in
stage IIIB.
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MAPK. It is notable that the CRL1579 cell line had a
homozygous deletion and X106S, resulting in an addition of
13 amino acids at the C-terminus. As far as we could
determine in the database, this alteration has not been
reported to date. Its biological significance, however, may
not be profound in the carcinogenesis of the melanocyte.
Mutations occurring at the stop codon are very rare; a 4-bp
insertion at the stop codon of the hMLH1 gene that caused
a 34 amino acid addition has also been reported (Papado-
poulos et al, 1994).
In this study, we demonstrated that mutations of the
BRAF gene in sporadic Japanese patients with melanoma
were less frequent than those in previous reports of
melanoma patients. Mutations were detected frequently in
SSM and ALM and in the phase of thin tumor thickness. The
RAF and RAS proteins play important roles in the same
pathway, and activation of this pathway is an early event in
melanoma. Further studies are necessary to clarify the key
molecular defects in melanoma, but there is a possibility of
controlling the development and progression of melanoma
by knockdown of this activated pathway.
Materials and Methods
Human cancer cell lines A total of 43 cancer cell lines were
analyzed in this study: 23 lung cancer cell lines, six melanoma cell
lines, six endometrial cancer cell lines, five gastric cancer cell lines,
and three lymphoma cell lines. All the 23 lung cancer cell lines
(1–87, 11–18, S-1, S-2, Sq-1, Sq-19, EBC-1, A549, LK79, LK87,
Lu-65, LU99A, RERF-LC-MS, RERF-LC-OK, HT-1, 35HTB, HS-24,
VMR-LCD, VMR-LCP, LC-1Sq, SBC-3, LK-2, and Sato T) have
been described in our previous papers (Han et al, 1999; Takeshita
et al, 1999). Of the six melanoma cell lines, five (HMV-I, HMV-II, SK-
MEL-28, G 361, and CRL 1579) were obtained from the Cell
Resource Center for Biomedical Research, Institute of Develop-
ment, Aging, and Cancer (IDAC), Tohoku University, Sendai, Japan,
and DEOC-1 was a generous gift from Dr Takashi Yamada at
Osaka Medical College (Takatsuki, Japan). All of the six endome-
trial cancer cell lines (KLE, HEC1-A, AN3CA, RL95-2, SK-UT-1B,
and Ishikawa 3H 12) were described previously (Sakurada et al,
1999). All of the five gastric cancer cell lines (MKN 7, KATO III,
AZ521, SH10TC, and GCIY) and three lymphoma cell lines
(KOIA 9LCL, NALM6, and KUDO EB) were also obtained from
IDAC. These cell lines were grown according to the suppliers’
recommendations.
Primary tumor samples A total of 35 specimens of primary
melanoma surgically removed from 35 Japanese patients in
Tohoku University Hospital were analyzed with the patients’ written
informed consent. The study was approved by the Ethical
Committee of Tohoku University School of Medicine and con-
ducted according to Declaration of Helsinki principles. Specimens
were formalin-fixed and paraffin-embedded. The clinical data and
histological subtypes of the patients are summarized in Table III.
DNA extraction In samples of relatively large primary tumor
specimens (tumor thickness more than 4 mm) with low frequencies
of normal cells (infiltrating lymphocytes or stromal cells), tumor
tissues were manually dissected under the microscope with sterile
needles from four consecutive 8 mm thick sections from the
formalin-fixed and paraffin-embedded blocks. In thin or infiltrative
growing primary tumor specimens, we used a LM100 laser capture
microdissection system (ARCTURUS, Mountain View, California)
from four consecutive 5 mm sections of the paraffin-embedded
blocks. Corresponding normal cells from either non-metastatic
lymph nodes or normal skin were also collected. For deparaffiniza-
tion, 1000 mL of xylene was added to the cells in 1500 mL
microcentrifuge tubes, mixed well using a vortex mixer for at least
5 min followed by two washes with 1000 mL absolute ethanol. Then
DNAs were extracted using QIAamp DNA Mini Kit (QIAGEN,
Valencia, California). DNAs of cell lines were extracted by the
methods described previously (Sambrook et al, 1989).
Mutation analyses Genomic DNA was amplified by the PCR
using the methods described previously (Kimura et al, 1996) with
the GeneAmp PCR system 9700 (Applied Biosystems, Foster City,
California). The nucleotide sequences of the PCR primers are listed
in Table IV; the primers were designed to amplify about 100-bp
because all the primary tumors were formalin-fixed. After the PCR,
bands of the products were cut from the gel, and DNA were
recovered by electro-elution. Then the DNA were ethanol pre-
cipitated and dissolved in 15 mL of TE. Concentrations of DNA were
checked by electrophoresis, and 150 fmol (2 mL) of the dissolved
DNA were subjected to nucleotide sequencing analysis using the
BigDye Terminator Cycle Sequencing Ready FS Reaction Kit
(Applied Biosystems, Foster City, California) and ABI PRISM 310
Genetic Analyzer (Applied Biosystems) by methods described
previously (Ouyang et al, 1997; Sakurada et al, 1997). Allele-
specific oligonucleotide (ASO) hybridization at 581C using [32P]-
end labeled oligomers RAF-MS (corresponding to mutant BRAF
sequence) and RAF-NS (corresponding to normal BRAF sequence)
was also performed to all primary melanoma specimens to confirm
the results of sequencing analysis according to methods described
previously (Sato et al, 1998). Nucleotide sequences of the
oligomers are also shown in Table IV.
Table III. Patients analyzed in this study
Histological subtype Number of cases Age  SD Male/female Tumor thickness  SD (mm) Clinical stagea
ALMb 15 69.0  14.2 12/3 4.3  2.6 3/7/4/1
SSMc 8 45.4  12.4 6/2 2.4  1.8 3/3/2/0
NMd 6 54.3  29.0 3/3 4.6  0.8 0/5/1/0
LMMe 5 75.2  7.3 1/4 3.8  1.6 0/4/1/0
Mucosal 1 53 0/1 4.2 0/1/0/0
Total 35 62.5  19.2 16/13 4.1  2.1 6/20/8/1
aAccording to AJCC (Kim et al 2002).
bAcral lentiginous melanoma.
cSuperficially spreading melanoma.
dNodular melanoma.
eLentigo maligna melanoma.
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Statistical analysis The statistical significance between the
prevalence of BRAF mutation and the histological subtype was
determined by Fisher’s exact test, and values of po0.05 were
considered as significant.
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